Back to results
US 12,534,536 B2Granted
Natural killer cells expressing a chimeric antigen receptor that binds CD38
AssigneeOnk Therapeutics Limited
InventorMichael Eamon Peter O'Dwyer
Life of this patent
Estimating the term…
Abstract
Disclosed herein are engineered natural killer cells that have been modified to express chimeric antigen receptors (CARs). The cells optionally contain other modifications that improve tumor specific cytotoxicity and homing to tumor sites. Also contemplated are methods for using the engineered natural killer cells to treat patients with cancer.
Claims8
An isolated mammalian natural killer (NK) cell that expresses a chimeric antigen receptor (CAR) that binds CD38, wherein the CAR comprises:
- i) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:
- 23 or 28;
- and
- ii) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:
- 1 or 7.
2 more elements
Dependencies are inferred from the claim text.